scholarly journals The efficacy and safety of bisphosphonates in patients with bone marrow edema syndrome/transient osteoporosis: A systematic literature review

2020 ◽  
Vol 22 ◽  
pp. 592-597
Author(s):  
Athanasios N. Ververidis ◽  
Konstantinos Paraskevopoulos ◽  
Anthimos Keskinis ◽  
Georgios I. Petkidis ◽  
Konstantinos Tilkeridis
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sharat Agarwal

Dear Editor, At the outset, I would like to congratulate the authors of the article published in your journal in the current issue entitled- Idiopathic Transient Osteoporosis during Pregnancy – Report of a Clinical Case JOCR November – December 2019 Volume 9 Issue 6 Page 54-57. However, I regret to mention that the workup mentioned in this article needs to be improved, before one can come to definitive diagnosis of Idiopathic Transient Osteoporosis during Pregnancy. I would like to highlight various perspectives, issues & concerns, the knowledge of which are must for the readers of this journal pertaining to this disorder. It is pertinent to mention no doubt the increasing utilization of magnetic resonance imaging (MRI) has allowed physicians to investigate edematous changes in bone marrow, a clinically important entity which was previously undetected on conventional radiographs. The first use of the term “bone marrow edema” was by Wilson et al in 1988, and the term “bone marrow edema syndrome” was described in 1993 after the investigation of histological specimens [1]. Later on, importantly Hayes et al. advocated that the term “transient bone marrow edema syndrome” should be used for patients in whom the bone marrow edema pattern was not accompanied by radiographic evidence of osteopenia [2]. And thus separating the two entities i.e. “the transient bone marrow edema syndrome” and “Transient Osteoporosis” Occurrence of hip pain during pregnancy is quite common, although transient osteoporosis as a condition causing this symptom is uncommonly seen. Clinicians should also be aware of intra-articular disorders such as loose bodies, and labral tears; peri-articular pathology such as tendinitis and bursitis; or extra-articular conditions such as referred pain from the lumbar spine, the sacroiliac joint, and or from nerve entrapment syndromes. So, a detailed history and physical examination is helpful to narrow the differential diagnoses, which, in turn, dictate the modal


2020 ◽  
Vol 22 ◽  
pp. 29-32 ◽  
Author(s):  
Athanasios N. Ververidis ◽  
Konstantinos Paraskevopoulos ◽  
Anthimos Keskinis ◽  
Nikolaos Adrianos Ververidis ◽  
Reichan Molla Moustafa ◽  
...  

2020 ◽  
Vol 2 (2) ◽  
pp. 51-54
Author(s):  
Alfredomaria Lurati ◽  
Antonella Laria ◽  
Paola Faggioli ◽  
Antonio Tamburello ◽  
Laura Castelnovo ◽  
...  

The bone marrow edema syndrome (BMES) is a severely disabling pain syndrome without a definite treatment and refers to transient clinical conditions with unknown pathogenic mechanism, such as transient osteoporosis of the hip, regional migratory osteoporosis, and reflex sympathetic dystrophy. Magnetic resonance imaging is used for early diagnosis and monitoring of its progression. Early differentiation from other aggressive conditions with longterm sequelae is essential in order to avoid unnecessary treatment. The aim of this monocentric trial was to test the efficacy and the safety of amino-bisphosphonate neridronate administered in two different regimens in patients with BMES. 192 patients with BMES secondary to osteoarthritis localized in the knee, hip, wrist or foot were randomly assigned to intravenous (iv) infusion of 100 mg neridronate given four times over 10 days (Group A, 72 subjects) or alternatively to iv infusions of 100 mg every 21 days over 3 months (Group B, 120 subjects). Magnetic resonance image (MRI) was performed at baseline and after 180 days. We assessed a 0-100 mm pain visual analogue scale (VAS) in each patient, too. Outcomes were MRI changes and VAS changes. A control group (35 patients) was enrolled too, treated conservatively with non-steroidal anti-inflammatory drugs and articular rest. We observed a significant improvement in MRI with the resolution of bone marrow lesions present at the baseline (P<0.01), without a significant difference between Group A and Group B. The VAS score decreased significantly during the study in both groups (P<0.05) without a significant difference between the two treatment groups (P>0.1). Both groups showed a significant clinical and radiologic improvement compared with the control group (P<0.001). In patients with BMES, the infusions of neridronate 100 mg every 21 days over 3 months or alternately every 3 days over 10 days were associated with clinically relevant and persistent benefits without significant differences between the two treatment schedules. These results provide conclusive evidence that the use of bisphosphonates, at appropriate doses, is the treatment of choice in BMES.


2002 ◽  
Vol 402 ◽  
pp. 171-175 ◽  
Author(s):  
Kyung-Hoi Koo ◽  
In-Oak Ahn ◽  
Hae-Ryong Song ◽  
Shin-Yoon Kim ◽  
John Paul Jones

Orthopedics ◽  
2001 ◽  
Vol 24 (1) ◽  
pp. 69-73
Author(s):  
Elias Ch Papadopoulos ◽  
Panayiotis J Papagelopoulos ◽  
Peter J Boscainos ◽  
Dimitrios Paschaloglou ◽  
Nikolaos D Gandaifis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document